NEUROGENETIC PHARMACEUTICALS

PRODUCTS & TECHNOLOGY

About Alzheimer’s

Alzheimer’s Disease (AD) is a progressive brain disease that slowly destroys memory and thinking skills. It is the most common cause of dementia among older people, with symptoms often appearing by the age of 60. The effects are loss of cognitive function such as thinking, remembering and reasoning to the extent of interfering with a person’s daily life.

  • Amyloid plaques deposited in the brain are believed to precede the onset of dementia by many years. These plaques are seeded by the “bad amyloid” (Αβ42), and cause or contribute to the cognitive decline of AD patients.
  • Alzheimer’s Disease afflicts more than 5.3 million Americans (33 million worldwide) at an annual cost of 200 billion dollars.
  • New cases of Alzheimer’s Disease are on the rise, and it is projected that by 2020 nearly 6 million people in the US will be initially diagnosed with Alzheimer’s dementia.
  • Early preventative treatment is dependent on the diagnosis of amyloid plaque pathology before dementia.
  • Amyloid plaques may be prevented and dementia avoided with the right medicine

Our Technology

Our patented technology of Gamma-Secretase Modulators (GSMs) is based on an innovative modulation of a key enzyme in the amyloid pathway, called γ-secretase. Our approach alters the production of amyloid proteins from the toxic form found in AD brains (Αβ42) to non-toxic forms (Αβ37 and Αβ38), which do not contribute to plaque deposition.

The GSM approach avoids inhibition of other γ-secretase targets potentially minimizing adverse side-effects. Therapies based on these compounds may be used to treat a broad range of amyloid-based diseases including cerebral vascular dementia, inclusion body myositis, Alzheimer’s dementia associated with Down’s Syndrome patients, and more.

Our Product

NGP has selected a clinical candidate, NGP 555, which is a small molecule modulator of the gamma-secretase complex. NGP 555 is a potent molecule, which crosses the blood-brain barrier and is effective in lowering the brain biomarkers Αβ42 and Αβ40 while showing an increase in the Αβ38 peptide with no effect on Notch processing. A key “proof of concept” study with NGP 555 showed significant reduction of amyloid plaques in the brains of mice harboring the human amyloid precursor protein.

NGP 555 represents a unique opportunity to clinically translate these biomarker findings to the reduction of amyloid pathology, culminating in the prevention of cognitive decline in Alzheimer’s Disease.

Patents

Mechanism of action, method of treatment, and solid dosage form formulations for oral dosing.

U.S.Patent 7,244,739 plus EPO, India, China, Canada, Mexico and other territories
U.S.Patent 7,781,442
U.S.Patent 7,799,808
U.S.Patent 8,017,629

Publications

Maria Z. Kounnas et. al. Neuron 67, 769-780, September 9, 2010.

“2-Aminothiazoles Derivatives as Potent Gamma-Secretase Modulators for the Prevention of Alzheimer’s Disease”: Soan Cheng, Ph.D., American Chemical Society, 2010

“Gamma-Secretase Modulators for the Prevention of Alzheimer’s Disease”: Maria Z. Kounnas, Ph.D., Society for Neurosciences, Nov., 2011

 

NEUROGENETIC PHARMACEUTICALS

ABOUT US

COMPANY INFORMATION

NeuroGenetic Pharmaceuticals is a privately held biotech company founded in 2009 with worldwide exclusive rights to a platform of gamma-secretase modulators.

Our patented technology includes multiple lead compounds for the treatment of neurodegenerative conditions, their composition of matter, mechanism of action and method of treatment.

 

MANAGEMENT

Board of Directors

William T. Comer, Ph.D.
CEO & Chairman, NeuroGenetic Pharmaceuticals, Inc.

Tom Reed, M.B.A.
CEO, Reed-Ventures

Barry Quart, Pharm.D.
President & CEO, Heron

 

Founders
William T. Comer, Ph.D.
CEO & Chairman, NeuroGenetic Pharmaceuticals, Inc.

Rudy Tanzi, Ph.D.
Professor Neurology, Harvard Medical School; Director, Genetics and Aging unit, MGH

Steven L. Wagner, Ph.D.
Department of Neurosciences, UC San Diego School of Medicine.

Principal Employees, Consultants and Advisors

William T. Comer, Ph.D.
CEO & Chairman, NeuroGenetic Pharmaceuticals, Inc.

Maria Z. Kounnas, Ph.D.
Senior Vice President, Research

Fred Reno, Ph.D.
Toxicology Consultant

Vijay N. Hingorani, M.D., Ph.D., MBA
Medical Consultant

David Holtzman, M.D., Ph.D.
Clinical Consultant

David McClure, Ph.D.
Regulatory Consultant

Janet McClean
Manager of Finance

 

NEUROGENETIC PHARMACEUTICALS

CONTACT US

NeuroGenetic Pharmaceuticals, Inc.
445 Marine View Ave., Suite 101
Del Mar, CA
92014
858-461-4480
858-461-4485